Bronchiectasis clinical trials at UCSF

1 in progress, 0 open to eligible people

PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
Sorry, not currently recruiting here
AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.
San Francisco, California and other locations

Last updated: November 21, 2025